Eliem Therapeutics is dropping a depression drug candidate and laying off 55% of staff in an attempt to stretch its cash runway, according to a Thursday press release.
https://www.pharmalive.com/wp-content/uploads/2023/02/BioSpacelayoff2-10-2023.jpg350625Christiane Truelovehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngChristiane Truelove2023-02-10 11:27:322023-02-10 11:27:32Eliem cuts MDD candidate, 55% of staff in Kv7 program pivot